Tandem Diabetes Care (NASDAQ:TNDM) Price Target Lowered to $37.00 at Robert W. Baird

Tandem Diabetes Care (NASDAQ:TNDM) had its price objective reduced by analysts at Robert W. Baird from $39.00 to $37.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “neutral” rating on the medical device company’s stock. Robert W. Baird’s price objective suggests a potential upside of 20.92% from the company’s current price.

TNDM has been the subject of several other reports. Canaccord Genuity Group initiated coverage on shares of Tandem Diabetes Care in a research note on Thursday, August 8th. They set a “buy” rating and a $57.00 price objective for the company. Royal Bank of Canada assumed coverage on shares of Tandem Diabetes Care in a report on Wednesday, October 2nd. They set an “outperform” rating and a $65.00 price target on the stock. Barclays raised their price objective on shares of Tandem Diabetes Care from $55.00 to $58.00 and gave the stock an “overweight” rating in a research note on Monday, August 5th. Canaccord Genuity Group began coverage on Tandem Diabetes Care in a research note on Thursday, August 8th. They set a “buy” rating and a $57.00 target price on the stock. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $45.00 price target on shares of Tandem Diabetes Care in a report on Monday, September 23rd. Five analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $54.25.

Tandem Diabetes Care Price Performance

NASDAQ:TNDM opened at $30.60 on Thursday. The firm has a market capitalization of $2.00 billion, a price-to-earnings ratio of -15.85 and a beta of 1.36. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.05 and a quick ratio of 2.38. The business has a 50 day simple moving average of $38.73 and a 200-day simple moving average of $41.81. Tandem Diabetes Care has a 1 year low of $13.82 and a 1 year high of $53.69.

Hedge Funds Weigh In On Tandem Diabetes Care

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Assetmark Inc. purchased a new stake in Tandem Diabetes Care during the third quarter worth $29,000. ORG Wealth Partners LLC purchased a new stake in shares of Tandem Diabetes Care during the 3rd quarter worth $30,000. ORG Partners LLC bought a new stake in Tandem Diabetes Care during the second quarter valued at about $31,000. Headlands Technologies LLC purchased a new position in Tandem Diabetes Care in the first quarter valued at about $35,000. Finally, Waldron Private Wealth LLC bought a new position in Tandem Diabetes Care in the third quarter worth about $50,000.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.